Is the Use of Monensin Another Trojan Horse for the Spread of Antimicrobial Resistance?

Author:

Carresi Cristina1ORCID,Marabelli Romano2,Roncada Paola3ORCID,Britti Domenico34ORCID

Affiliation:

1. Veterinary Pharmacology Laboratory, Department of Health Sciences, Interregional Research Center for Food Safety and Health IRC-FSH, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy

2. World Organization for Animal Health, 75017 Paris, France

3. Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy

4. Interdepartmental Center Veterinary Service for Human and Animal Health, University “Magna Graecia” of Catanzaro, CISVetSUA, 88100 Catanzaro, Italy

Abstract

Antimicrobial resistance (AMR) is a complex and somewhat unpredictable phenomenon. Historically, the utilization of avoparcin in intensive farming during the latter part of the previous century led to the development of resistance to vancomycin, a crucial antibiotic in human medicine with life-saving properties. Currently, in the European Union, there is a growing reliance on the ionophore antibiotic monensin (MON), which acts both as a coccidiostat in poultry farming and as a preventative measure against ketosis in lactating cows. Although many researchers claim that MON does not induce cross-resistance to antibiotics of clinical relevance in human medicine, some conflicting reports exist. The numerous applications of MON in livestock farming and the consequent dissemination of the compound and its metabolites in the environment require further investigation to definitively ascertain whether MON represents a potential vector for the propagation of AMR. It is imperative to emphasize that antibiotics cannot substitute sound animal husbandry practices or tailored dietary regimens in line with the different production cycles of livestock. Consequently, a rigorous evaluation is indispensable to assess whether the economic benefits associated with MON usage justify its employment, also considering its local and global environmental ramifications and the potential risk of instigating AMR with increased costs for its control.

Funder

AgrInfra Calabria

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology

Reference73 articles.

1. Unknown Risk on the Farm: Does Agricultural Use of Ionophores Contribute to the Burden of Antimicrobial Resistance;Wong;mSphere,2019

2. Distinguishing between resistance, tolerance and persistence to antibiotic treatment;Brauner;Nat. Rev. Microbiol.,2016

3. (1997). Commission Directive 97/72/EC of 15 December 1997 amending Council Directive 70/524/EEC concerning additives in animal feeding (Text with EEA relevance). Off. J. L, 351, 0055–0059.

4. FDA Department of Health and Human Services (2004). Monensin approval. Fed. Regist. (Rules Regul.), 69, 68783–68784.

5. European Council (2007). Council Regulation (EC) No 108/2007 of 5 February 2007 Amending Regulation (EC) No 1356/2004 as Regards the Conditions for Authorisation of the Feed Additive Elancoban, Belonging to the Group of Coccidiostats and Other Medicinal Substances (Text. with EEA Relevance). Off. J. Eur. Union, 4–5. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32007R0108&qid=1706387362985.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3